Promising Phase II Data For Sanofi’s Hemlibra Rival Fitusiran
Gene Therapy Also Approaching Market
Executive Summary
Sanofi has unveiled encouraging Phase II data for fitusiran, a novel RNA-based hemophilia therapy which could eventually challenge Roche’s blockbuster Hemlibra.
You may also be interested in...
No Looking Back For Sanofi In R&D Turnaround Quest
Sanofi's R&D operation has shaken the dust of diabetes off its feet with an update on its ambitious pipeline plans at an R&D day event.
BioMarin’s Hemophilia Gene Therapy Still Works After Four Years, But Effects Tail Off
Latest results show a show decline in effects, but still offers freedom from injections with almost no bleeds recorded in 13 patients.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.